Skip to content

Trial Summary

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors



ACTRN/NCT /ethics:


Scientific title:

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Sponsor / Cooperative group:

Antengene Corporation (Antengene Biologics Limited )

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2023-02-01
Anticipated End Date2026-06-30

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead/Kate Penta
Phone08 8359 2565
Principal InvestigatorSarwan Bishnoi
Recruitment StatusRecruiting